COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
HCQ study #57 of 264
6/10 Late treatment study
Wang et al., medRxiv, doi:10.1101/2020.06.11.20128926 (Peer Reviewed)
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System
Source   PDF   Share   Tweet
Database analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96, p = 0.82, and HCQ+AZ OR 0.94, p = 0.63

Wang et al., 6/10/2020, retrospective, database analysis, USA, North America, peer-reviewed, 3 authors.
risk of death, 5.8% lower, RR 0.94, p = 0.63, treatment 1866, control 5726, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 264 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit